Core Viewpoint - The article emphasizes the importance of scientific talent in driving innovation and investment in cities, highlighting the trend of venture capitalists (VCs) seeking projects in research institutions where scientific expertise is concentrated [2][11]. Group 1: Company Overview - Li Bo Bio recently completed nearly 100 million yuan in Pre-A round financing, led by Tian Shi Li Capital and Pan Lin Capital, with participation from Yuan Sheng Venture Capital and Zhejiang Province's "4+1" biomedicine and high-end equipment industry fund [3][4]. - Founded in September 2022, Li Bo Bio focuses on RNA research, leveraging AI to discover stable tertiary structures in RNA and predict their folding shapes and small molecule binding pockets [6][4]. - The founding team includes notable scientists such as Professor Zhou Yaoqi, Dr. Zhan Jian, and Dr. Fang Chao, who bring extensive experience in structural biology and small molecule drug development [4][6]. Group 2: Research Institutions - Shenzhen Bay Laboratory, established in 2018, has over 200 staff and focuses on basic and applied research, promoting the transformation of research results into industrial applications [8][9]. - The laboratory has collaborated with major companies like Huawei and has incubated several tech companies, including Li Bo Bio and Bay Shadow Technology [8][9]. - The article notes that the concentration of scientific talent in research institutions is attracting significant attention from VCs, as these institutions are seen as key sources of innovative technology [11][12]. Group 3: Investment Trends - There is a growing trend of VCs targeting research institutions and university laboratories for investment opportunities, recognizing that hard technology is likely to be a major investment theme for the next decade [11][12]. - The article highlights that research institutions provide a unique environment conducive to innovation, free from the academic pressures found in universities, allowing for more practical product development [13]. - The shift in focus towards research institutions is reshaping the investment landscape, with the concentration of scientific talent becoming a critical factor in determining a city's future potential [13].

Core Viewpoint - A comprehensive strategic cooperation agreement has been signed between China Antibody and the Hong Kong Advanced Institute of Zhongshan University, aiming to integrate research and industrial resources to advance biopharmaceutical innovation and clinical translation for better treatment options for global patients [3][4]. Group 1: Cooperation Agreement Details - The cooperation agreement includes five key areas: joint research, shared facility resources, full-chain technical support, drug development, and training and knowledge exchange [3]. - The collaboration aims to enhance professional research capabilities in treating degenerative diseases through training programs and personnel exchanges [3][4]. Group 2: Institutional Goals and Capabilities - The Hong Kong Advanced Institute of Zhongshan University focuses on addressing global medical challenges and aims to precisely connect research resources with industrial strengths [4]. - The institute possesses strong capabilities in animal model construction, regulatory expertise, and joint laboratory facilities, which will synergize with China Antibody's practical experience in antibody drug development [4]. - Established in October of the previous year, the institute integrates teaching, research, and technology transfer, with a focus on biomedicine, applied mathematics, and interdisciplinary humanities and social sciences [4].

近日，华南农业大学校长薛红卫教授率队赴广州市从化区调研乡村振兴工作，亲切慰问暑期 在从化开展"万名学子乡村大调研行动"的师生队伍，开展了2025年"双百行动"联席工作会 议，推动校地合作向纵深发展。从化区委副书记欧阳可员、副区长孙凌洁等参加相关活动。 走访调研察实情 产教融合育新功 在从化区良口镇米埗村，薛红卫一行实地听取村情介绍与发展规划，详细了解灌渠精神、乡 村建设现状与需求。随后，薛红卫与正在当地开展暑期实践的师生亲切座谈，认真倾听植物 保护学院"橘光行动"队、林学与风景园林学院"泉乡焕彩突击队"、动物科学学院"从化大调 研"团队等7支特色队伍的实践分享——从绿色种养技术推广到农文旅产业服务，从乡村深度 调研到留守儿童关爱，师生们立足专业特色，将课堂所学转化为服务乡村的具体行动，以扎 实成果展现了华农学子的责任担当。 作为深化校地合作的重要机制，实地调研后，华农与从化召开2025年"双百行动"联席工作会 议。区委副书记欧阳可员，副区长孙凌洁，华南农业大学副校长陈乐天，广东女子职业技术 学院副书记何树莲等6所"双百行动"结对高校代表，以及区相关职能单位负责人齐聚一堂， 总结阶段性成果，共谋深化合作新路径。 ...

Core Viewpoint - The article discusses the significant advancements made by Tahoe Therapeutics in developing AI models for simulating living cells, particularly in the context of cancer treatment [3][6]. Group 1: Company Overview - Tahoe Therapeutics recently raised $30 million in funding, bringing its valuation to $120 million, to build AI models of living cells [3]. - The company has developed a scalable method to quickly generate key biological data necessary for AI models, aiming to discover new cancer treatments [3][15]. - Tahoe's CEO, Nima Alidoust, stated that the company has developed a drug candidate targeting a major cancer subtype and is currently conducting preclinical studies required by the FDA [4][15]. Group 2: Technological Advancements - Digital simulation of living cells is considered a "holy grail" in biology, as it could allow for precise predictions of cancer cell responses to various drugs, significantly enhancing research efficiency in oncology [6]. - Tahoe Therapeutics is focused on creating AI models capable of running such simulations, having previously launched the Tahoe-100M dataset, which includes 100 million data points on cancer cell interactions with over 1,000 different molecules [7][10]. - The Tahoe-100M dataset is crucial for training AI models, providing information on how cells respond to various molecules, thereby improving the accuracy of predictions [7][11]. Group 3: Collaborative Efforts and Achievements - Following the release of the Tahoe-100M dataset, the Arc Institute developed an open-source virtual cell model called State, which utilizes Tahoe-100M as part of its training data [9]. - In benchmark tests, the Arc Institute found that their model's accuracy was twice that of other AI models, outperforming simpler machine learning programs [11]. - Tahoe has partnered with Kepler AI to create TahoeDive, an AI agent designed for biologists to query and analyze the Tahoe-100M dataset, which has been utilized by hundreds of researchers globally [11][15]. Group 4: Future Goals and Expansion - Tahoe aims to expand its dataset to include over one billion single-cell data points to support its virtual cell model development [15]. - The company’s ability to rapidly scale data production is seen as a key differentiator compared to other AI drug discovery firms [15]. - Tahoe's core team consists of experienced professionals from prestigious institutions, enhancing its capability in drug discovery and development [21][22].

Group 1 - The core viewpoint of the article highlights the collaboration between South China Agricultural University and Conghua District in promoting rural revitalization through practical actions and research initiatives [1][3][5] - The university's president, Xue Hongwei, emphasized the importance of student involvement in rural projects and the need for a strong organizational framework to support these initiatives [5][10] - The "Double Hundred Action" serves as a mechanism for deepening cooperation between the university and local government, focusing on addressing development needs and enhancing resource sharing [8][10] Group 2 - During the visit, the university's teams shared their practical experiences in various fields, including green agricultural techniques and community support for left-behind children, showcasing the application of academic knowledge in real-world scenarios [3][5][13] - A joint meeting was held to summarize progress and discuss new paths for collaboration, with representatives from multiple educational institutions and local government [8][10] - The university plans to establish a collaborative platform for research and development in the biopharmaceutical sector, aiming to enhance the local economy and support high-quality development in the Guangdong-Hong Kong-Macao Greater Bay Area [11][13]

中国抗体-B(03681)发布公告，于2025年8月12日，公司与中山大学香港高等研究院有限公司(中山大学香 港高等研究院或SYSU-IAS)(连同公司统称订约方)订立全面战略合作协议(合作协议)，据此，订约方同 意开展为期三年的合作，以于生物医学领域进行联合研发。 本合作协议旨在借助公司与中山大学香港高等研究院的联合优势，加速创新药物的发展，并推动全球范 围内科研成果向临床应用的转化。该合作将以项目驱动模式开展，以资源共享及高效沟通为核心框架。 该模式将使集团可直接利用中山大学香港高等研究院完备的实验室设施、实验动物供应资源(尤其非灵 长类动物)和宝贵的数据资产，此乃推动创新药研以及公司研发可持续发展的关键要素。董事会认为此 项战略合作构建了一个互利共赢的框架，有助于推动增长并确保长期可持续性。此次合作与公司推进其 在研创新药组合的发展战略相符。 中山大学香港高等研究院是中山大学设立的研究机构，于2024年2月8日在香港成立。研究院致力于高端 学术研究、跨学科合作，并促进中国内地与香港在科技、人文等领域的交流与合作。 ...

本合作协议旨在借助公司与中山大学香港高等研究院的联合优势，加速创新药物的发展，并推动全球范 围内科研成果向临床应用的转化。该合作将以项目驱动模式开展，以资源共享及高效沟通为核心框架。 该模式将使集团可直接利用中山大学香港高等研究院完备的实验室设施、实验动物供应资源(尤其非灵 长类动物)和宝贵的数据资产，此乃推动创新药研以及公司研发可持续发展的关键要素。董事会认为此 项战略合作构建了一个互利共赢的框架，有助于推动增长并确保长期可持续性。此次合作与公司推进其 在研创新药组合的发展战略相符。 董事会认为，合作协议为双方提供了宝贵的机会，使其能够充分发挥各自的资源和专业知识，实现互利 共赢并产生协同效应。因此，董事会认为订立合作协议属公平合理，并符合公司及其股东的整体利益。 联合研究工作：订约方将利用彼此的专业知识联合开展科学研究，包括发现研究、靶点阐释及严重疾病 动物模型开发；中山大学香港高等研究院应负责为该等联合研究提供实验场地和动物。 设施共用：中山大学香港高等研究院应允许本公司使用其位于中国内地深圳市深圳福田国际生物医药产 业园的实验室，以进行联合科学研究。实验室应被正式指定为"中山大学香港高等研究院—中国抗 ...

Market Overview - The Hong Kong stock market showed mixed results with the Hang Seng Technology Index rising by 0.25%, briefly surpassing the 25,000-point mark, while the Hang Seng Index increased by 0.32% and the Hang Seng Technology Index fell by 0.38% [1] Sector Performance - Large technology stocks exhibited divergent trends, with Xiaomi up by 1.77%, NetEase rising by 1%, and JD.com and Meituan also in the green, while Kuaishou plummeted over 9%, Alibaba dropped by 1.6%, and Baidu fell by 1.34% [1] - The semiconductor sector was boosted by rumors, leading to a surge in shares of Cambricon Technology, which hit the 20% daily limit, driving up Hong Kong semiconductor stocks collectively, with Hongguang Semiconductor rising by 11.5% and SMIC and Hua Hong Semiconductor increasing by over 5% [1] - Insurance stocks performed well as a result of a scheduled interest rate cut and an increase in the proportion of dividend insurance, with China Pacific Insurance leading the gains, rising over 6% [1] - Other active sectors included coal, dairy products, Apple concept stocks, Chinese brokerage firms, domestic property stocks, oil, brain-computer interface concepts, and shipping stocks [1] Declining Sectors - The rare earth concept stocks and paper industry stocks experienced significant declines, while the biopharmaceutical sector showed a high open but low close, with BGI Genomics and Livzon Pharmaceutical leading the losses among innovative drug stocks [1] - Logistics, vocational education, and military industry stocks also saw declines [1]

Core Viewpoint - Exosomes, small vesicles released by living cells, are recognized as a promising area in biomedicine, with applications in disease diagnosis, cell therapy, drug delivery, and regenerative medicine. The regulatory inclusion of extracellular vesicles (EVs) as advanced therapy medicinal products (ATMPs) marks a significant step towards their industrial application, although challenges remain in technology, standards, and interdisciplinary collaboration [2]. Group 1: Exosome Overview - Exosomes are tiny vesicles with a diameter of 30-150 nm, serving as messengers for intercellular communication and signal transmission. They contain various bioactive substances, including proteins, functional DNA fragments, mRNAs, and miRNAs [2]. - The National Medical Products Administration (NMPA) in China has recognized EVs as part of the ATMP category, indicating a move towards regulatory standardization in the development of exosome-related products [2]. Group 2: Challenges in the Industry - The exosome industry faces three main challenges: the need for breakthroughs in key technologies, the establishment of industry standards, and the enhancement of interdisciplinary collaborative innovation [2]. Group 3: Upcoming Event - An online seminar titled "First Exosome Innovation Technology and Application Progress" will be held on August 12, 2025, organized by Instrument Information Network, focusing on advancements in exosome extraction, characterization, and applications in disease diagnosis and treatment [3][5]. - The seminar will feature various sessions, including topics on standardization, single-molecule characterization, clinical applications, and innovative detection methods related to exosomes [6].

Core Points - The company, Shanghai Medicilon Inc., was established as a joint-stock company based on the net asset value of Shanghai Medicilon Biomedicine Co., Ltd. and registered in Shanghai [1][2] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 5, 2019, after issuing 15.5 million shares [1][3] - The registered capital of the company is RMB 134.352184 million [2] Chapter Summaries Chapter 1: General Provisions - The purpose of the articles is to protect the legal rights of the company, shareholders, and creditors, and to regulate the company's organization and behavior [1] - The company is a permanent joint-stock company and all assets are divided into equal shares, with shareholders liable only to the extent of their subscribed shares [2] Chapter 2: Business Objectives and Scope - The company's business objective is to integrate and optimize resources to provide high-quality products and services, ensuring sustainable development and maximizing shareholder returns [3] - The business scope includes research and development of drugs for AIDS, cancer sensitizers, gene engineering vaccines, and biopharmaceutical intermediates [4] Chapter 3: Share Issuance - The company's shares are issued in the form of stocks, adhering to principles of openness, fairness, and justice [4] - The total number of shares issued by the company is 134.352184 million, all of which are ordinary shares [5] Chapter 4: Shareholders and Shareholders' Meeting - Shareholders have rights to dividends, participate in meetings, supervise the company, and request information [12] - The company must hold an annual shareholders' meeting within six months after the end of the previous fiscal year [44] - The company can only issue shares or reduce capital under specific legal procedures and with shareholder approval [22][23] Chapter 5: Shareholder Rights and Obligations - Shareholders must comply with laws and the articles of association, and they cannot withdraw their shares except in legally specified circumstances [38] - Shareholders holding more than 5% of voting shares must report any pledges of their shares [39] Chapter 6: Shareholders' Meeting Procedures - The shareholders' meeting is the company's authority, deciding on business policies, electing directors, and approving financial budgets [41] - The meeting must be convened with proper notice, and shareholders can participate in person or by proxy [60][61] Chapter 7: Voting and Resolutions - Resolutions can be ordinary or special, with ordinary resolutions requiring more than half of the voting rights and special resolutions requiring two-thirds [77][78] - The company must disclose voting results, especially for matters affecting minority investors [80]